BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24474687)

  • 1. Low density lipoprotein receptor-related protein 1 (LRP1)-mediated endocytic clearance of a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4): functional differences of non-catalytic domains of ADAMTS-4 and ADAMTS-5 in LRP1 binding.
    Yamamoto K; Owen K; Parker AE; Scilabra SD; Dudhia J; Strickland DK; Troeberg L; Nagase H
    J Biol Chem; 2014 Mar; 289(10):6462-6474. PubMed ID: 24474687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRP-1-mediated endocytosis regulates extracellular activity of ADAMTS-5 in articular cartilage.
    Yamamoto K; Troeberg L; Scilabra SD; Pelosi M; Murphy CL; Strickland DK; Nagase H
    FASEB J; 2013 Feb; 27(2):511-21. PubMed ID: 23064555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Research progress of a disintegrin and metalloproteinase with thrombospondin motif 4 and 5 in osteoarthritis].
    Ji Q; Zhang Q; Wang Y
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2013 Sep; 27(9):1080-4. PubMed ID: 24279019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases.
    Troeberg L; Fushimi K; Khokha R; Emonard H; Ghosh P; Nagase H
    FASEB J; 2008 Oct; 22(10):3515-24. PubMed ID: 18632849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aggrecanase and aggrecan degradation in osteoarthritis: a review.
    Huang K; Wu LD
    J Int Med Res; 2008; 36(6):1149-60. PubMed ID: 19094423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4.
    Gendron C; Kashiwagi M; Lim NH; Enghild JJ; Thøgersen IB; Hughes C; Caterson B; Nagase H
    J Biol Chem; 2007 Jun; 282(25):18294-18306. PubMed ID: 17430884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MMP-13 is constitutively produced in human chondrocytes and co-endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1.
    Yamamoto K; Okano H; Miyagawa W; Visse R; Shitomi Y; Santamaria S; Dudhia J; Troeberg L; Strickland DK; Hirohata S; Nagase H
    Matrix Biol; 2016 Dec; 56():57-73. PubMed ID: 27084377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggravation of ADAMTS and matrix metalloproteinase production and role of ERK1/2 pathway in the interaction of osteoarthritic subchondral bone osteoblasts and articular cartilage chondrocytes -- possible pathogenic role in osteoarthritis.
    Prasadam I; Crawford R; Xiao Y
    J Rheumatol; 2012 Mar; 39(3):621-34. PubMed ID: 22247346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5.
    Song RH; Tortorella MD; Malfait AM; Alston JT; Yang Z; Arner EC; Griggs DW
    Arthritis Rheum; 2007 Feb; 56(2):575-85. PubMed ID: 17265492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactive-site mutants of N-TIMP-3 that selectively inhibit ADAMTS-4 and ADAMTS-5: biological and structural implications.
    Lim NH; Kashiwagi M; Visse R; Jones J; Enghild JJ; Brew K; Nagase H
    Biochem J; 2010 Oct; 431(1):113-22. PubMed ID: 20645923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing.
    Kashiwagi M; Enghild JJ; Gendron C; Hughes C; Caterson B; Itoh Y; Nagase H
    J Biol Chem; 2004 Mar; 279(11):10109-19. PubMed ID: 14662755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cleavage of biglycan by aggrecanases.
    Melching LI; Fisher WD; Lee ER; Mort JS; Roughley PJ
    Osteoarthritis Cartilage; 2006 Nov; 14(11):1147-54. PubMed ID: 16806997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis.
    Verma P; Dalal K
    J Cell Biochem; 2011 Dec; 112(12):3507-14. PubMed ID: 21815191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCN1 (Cyr61) Is Overexpressed in Human Osteoarthritic Cartilage and Inhibits ADAMTS-4 (Aggrecanase 1) Activity.
    Chijiiwa M; Mochizuki S; Kimura T; Abe H; Tanaka Y; Fujii Y; Shimizu H; Enomoto H; Toyama Y; Okada Y
    Arthritis Rheumatol; 2015 Jun; 67(6):1557-67. PubMed ID: 25709087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The C-terminal domains of ADAMTS-4 and ADAMTS-5 promote association with N-TIMP-3.
    Troeberg L; Fushimi K; Scilabra SD; Nakamura H; Dive V; Thøgersen IB; Enghild JJ; Nagase H
    Matrix Biol; 2009 Oct; 28(8):463-9. PubMed ID: 19643179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of aggrecanases from the ADAMTS family and aggrecan neoepitope formation during in vitro chondrogenesis of human mesenchymal stem cells.
    Boeuf S; Graf F; Fischer J; Moradi B; Little CB; Richter W
    Eur Cell Mater; 2012 May; 23():320-32. PubMed ID: 22562232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Aggrecanases for Osteoarthritis Therapy: From Zinc Chelation to Exosite Inhibition.
    Cuffaro D; Ciccone L; Rossello A; Nuti E; Santamaria S
    J Med Chem; 2022 Oct; 65(20):13505-13532. PubMed ID: 36250680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Disintegrin and Metalloproteinase with Thrombospondin Motifs-5 (ADAMTS-5) Forms Catalytically Active Oligomers.
    Kosasih HJ; Last K; Rogerson FM; Golub SB; Gauci SJ; Russo VC; Stanton H; Wilson R; Lamande SR; Holden P; Fosang AJ
    J Biol Chem; 2016 Feb; 291(7):3197-208. PubMed ID: 26668318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggrecanases in the human synovial fluid at different stages of osteoarthritis.
    Zhang E; Yan X; Zhang M; Chang X; Bai Z; He Y; Yuan Z
    Clin Rheumatol; 2013 Jun; 32(6):797-803. PubMed ID: 23370724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of human neutralizing antibody to ADAMTS4 (aggrecanase-1) and ADAMTS5 (aggrecanase-2).
    Shiraishi A; Mochizuki S; Miyakoshi A; Kojoh K; Okada Y
    Biochem Biophys Res Commun; 2016 Jan; 469(1):62-69. PubMed ID: 26612259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.